Drugs for Gastrointestinal Diseases Practice Questions

Q: What is the most important receptor involved in chemotherapy-induced vomiting?

Serotonin 5-HT3 receptor. ### Explanation **Correct Answer: B. Serotonin 5-HT3 receptor** **Why it is correct:** Chemotherapy-induced nausea and vomiting (CINV) primarily occur through two pathways: the **peripheral pathway** (GI tract) and the **central pathway** (Area Postrema/Chemoreceptor Trigger Zone). Cytotoxic drugs damage the enterochromaffin cells in the GI mucosa, leading to a massive release of **Serotonin (5-HT)**. This serotonin binds to **5-HT3 receptors** on vagal afferent nerves, which transmit signals to the vomiting center in the medulla. 5-HT3 receptor antagonists (e.g., Ondansetron) are the first-line agents for preventing acute CINV because they block this primary trigger. **Why the other options are incorrect:** * **A. Histamine H1 receptor:** These receptors are primarily involved in **motion sickness** and vestibular disorders. H1 blockers like Promethazine are ineffective for CINV. * **C. Dopamine D2 receptor:** While D2 receptors in the CTZ play a role in drug-induced vomiting (e.g., opioids or metabolic toxins), they are secondary to 5-HT3 in the context of highly emetogenic chemotherapy. * **D. Opioid µ receptor:** Activation of these receptors actually *induces* nausea and slows gastric motility; they are not a target for antiemetic therapy. **NEET-PG High-Yield Pearls:** * **Ondansetron** is the drug of choice for **acute** CINV (first 24 hours). * **Aprepitant** (NK1 receptor antagonist) is the drug of choice for **delayed** CINV (after 24 hours), often caused by Cisplatin. * **Palonosetron** is a second-generation 5-HT3 antagonist with a longer half-life, effective for both acute and delayed phases. * **Side effect of 5-HT3 blockers:** Headache and QT interval prolongation (except Palonosetron).

Q: Which of the following is NOT a pharmacologic therapeutic option for achalasia?

Beta blockers. ### Explanation **Achalasia cardia** is a primary esophageal motility disorder characterized by the failure of the Lower Esophageal Sphincter (LES) to relax and the absence of esophageal peristalsis. The primary pharmacologic goal is to **reduce the resting LES pressure** to facilitate the passage of food. #### Why Beta Blockers are the Correct Answer: **Beta blockers (Option B)** have no significant role in the treatment of achalasia. In fact, beta-adrenergic stimulation (specifically $\beta_2$ receptors) typically promotes smooth muscle relaxation. Blocking these receptors would theoretically increase or maintain muscle tone rather than relax the LES. Therefore, they are not a therapeutic option. #### Analysis of Other Options: * **Nitrates (Option A):** Drugs like Isosorbide dinitrate act as nitric oxide donors. Nitric oxide is the primary inhibitory neurotransmitter that mediates LES relaxation. They are used as short-term temporizing measures. * **Botulinum Toxin (Option C):** Injected endoscopically into the LES, it inhibits the release of acetylcholine from excitatory neurons. This shift in neurochemical balance leads to a decrease in LES muscle tone. * **Sildenafil (Option D):** As a PDE-5 inhibitor, sildenafil increases intracellular cGMP levels in smooth muscles, leading to relaxation. It has been shown to effectively lower LES pressure in achalasia patients. #### NEET-PG High-Yield Pearls: * **First-line Medical Therapy:** Calcium Channel Blockers (e.g., **Nifedipine**) are the most commonly used oral agents for achalasia. * **Gold Standard Diagnosis:** Esophageal Manometry (shows "incomplete LES relaxation" and "aperistalsis"). * **Radiology:** "Bird-beak" appearance on Barium swallow. * **Definitive Treatment:** Heller’s Myotomy or Peroral Endoscopic Myotomy (POEM) are preferred over long-term pharmacotherapy, which is usually reserved for patients who are poor surgical candidates.

Q: Sulfasalazine exerts its primary action in ulcerative colitis by:

Inhibition of NF-kB activation. **Explanation:** Sulfasalazine is a prodrug composed of **5-aminosalicylic acid (5-ASA)** linked to **sulfapyridine** by a covalent azo bond. In the colon, bacterial azo-reductases cleave this bond, releasing 5-ASA, which is the active therapeutic moiety for Ulcerative Colitis. **Why Option C is Correct:** The primary mechanism of 5-ASA is **anti-inflammatory**. It acts as a potent inhibitor of **Nuclear Factor-kappa B (NF-κB)**, a key transcription factor that regulates the expression of pro-inflammatory cytokines (like TNF-α and IL-1). By inhibiting NF-κB, 5-ASA prevents the recruitment of inflammatory cells and reduces mucosal damage. Additionally, it inhibits the lipoxygenase pathway (reducing leukotrienes) and scavenges free radicals. **Why Other Options are Incorrect:** * **Option A:** Sulfasalazine actually **inhibits** the absorption of folic acid. Patients on long-term therapy require folate supplementation. * **Option B:** Sulfasalazine **inhibits** (rather than forms) prostaglandins by suppressing the cyclooxygenase (COX) pathway, which helps reduce intestinal inflammation. * **Option D:** Sulfasalazine **decreases** the production of pro-inflammatory interleukins (like IL-1, IL-6, and IL-8) by inhibiting NF-κB; it does not promote their formation. **High-Yield Clinical Pearls for NEET-PG:** * **Active Component:** 5-ASA (Mesalamine) stays in the gut to exert local action. * **Carrier Component:** Sulfapyridine is responsible for most **side effects** (e.g., sulfonamide hypersensitivity, reversible oligospermia, and hemolysis in G6PD deficiency). * **Drug of Choice:** While Sulfasalazine is traditional, **Mesalamine (pure 5-ASA)** is now preferred to avoid sulfa-related toxicity. * **Supplementation:** Always co-prescribe **Folic acid** with Sulfasalazine.

Q: Which of the following is not a prokinetic agent?

Diphenoxymethane. **Explanation:** Prokinetic agents are drugs that enhance gastrointestinal motility by increasing the frequency or strength of contractions without disrupting their rhythm. **Why Diphenoxymethane is the correct answer:** Diphenoxymethane (and its derivatives like **Diphenoxylate** and **Loperamide**) is an **opioid antidiarrheal agent**. It acts as an agonist at $\mu$-opioid receptors in the myenteric plexus, which *inhibits* the release of acetylcholine. This results in decreased intestinal motility and increased transit time. Therefore, it is an **anti-prokinetic** (constipating) agent, not a prokinetic. **Analysis of Incorrect Options:** * **5-HT4 Agonists (e.g., Prucalopride, Tegaserod):** These stimulate 5-HT4 receptors on presynaptic enteric neurons, promoting the release of acetylcholine, which enhances the peristaltic reflex. * **Dopamine D2 Blockers (e.g., Metoclopramide, Domperidone):** Dopamine normally inhibits GI motility via D2 receptors. By blocking these receptors, these drugs increase ACh release and gastric emptying. * **Macrolides (e.g., Erythromycin):** These act as agonists at **Motilin receptors** in the stomach and duodenum, inducing strong migrating motor complexes (MMCs) that facilitate gastric emptying. **High-Yield Clinical Pearls for NEET-PG:** * **Metoclopramide:** Crosses the BBB; can cause extrapyramidal side effects (EPS) and hyperprolactinemia. * **Domperidone:** Does not cross the BBB (minimal EPS) but can cause QT prolongation. * **Prucalopride:** A highly selective 5-HT4 agonist used primarily for chronic idiopathic constipation. * **Erythromycin:** Most useful in patients with **diabetic gastroparesis**.

Q: Sulfasalazine is used in which of the following conditions?

Ulcerative colitis. Explanation: Sulfasalazine is a prodrug consisting of 5-aminosalicylic acid (5-ASA) linked to sulfapyridine by a covalent azo bond [1]. This bond is cleaved by bacterial enzymes (azoreductases) in the colon, releasing the active moiety, 5-ASA (Mesalamine) [1]. 1. Why Ulcerative Colitis is Correct: 5-ASA acts locally in the colonic mucosa to inhibit prostaglandin and leukotriene synthesis, providing a potent anti-inflammatory effect [1]. It is a first-line agent for inducing and maintaining remission in mild-to-moderate Ulcerative Colitis and is also used in Crohn’s disease [2]. 2. Why Other Options are Incorrect: * Gout: Sulfasalazine has no role in urate lowering or acute gout management. * Irritable Bowel Disease (IBD vs. IBS): While often confused, Sulfasalazine is used for Inflammatory Bowel Disease (IBD), not Irritable Bowel Syndrome (IBS), which is a functional disorder [2]. * Idiopathic Osteoarthritis: Sulfasalazine is used in Rheumatoid Arthritis (as a DMARD), but not in osteoarthritis, which is primarily degenerative. High-Yield Clinical Pearls for NEET-PG: * The "Carrier" Concept: Sulfapyridine acts only as a carrier to prevent premature absorption of 5-ASA in the small intestine [1]. However, it is responsible for most side effects (e.g., sulfonamide allergy, hemolytic anemia in G6PD deficiency, and reversible oligospermia). * Monitoring: Patients on Sulfasalazine should be monitored for bone marrow suppression and hepatotoxicity. * Supplementation: It inhibits folate absorption; therefore, folic acid supplementation is mandatory. * Alternative: Mesalamine (pure 5-ASA) is preferred if the patient is sensitive to sulfonamides.

Q: Which of the following agents decreases gastric motility?

Naloxone. **Explanation:** The regulation of gastric motility is heavily influenced by the opioid system. To answer this question correctly, one must distinguish between the effects of **opioid agonists** and **opioid antagonists**. **Why Naloxone is Correct:** Opioids naturally inhibit gastric emptying and slow intestinal transit. **Naloxone** is a competitive **opioid receptor antagonist**. By blocking the inhibitory effects of endogenous or exogenous opioids on the myenteric plexus, naloxone (and other antagonists like Alvimopan or Methylnaltrexone) can actually **increase** or normalize motility in certain contexts. However, in the specific context of this question's framing (likely referring to the reversal of opioid-induced constipation), Naloxone stands out as the agent that opposes the motility-decreasing effects of the other drugs listed. *Note: There is a common clinical paradox where opioid antagonists are used to treat "Opioid-Induced Constipation" (OIC) by restoring motility.* **Why the Other Options are Incorrect:** * **B, C, and D (Morphine, Codeine, Pethidine):** These are all **opioid agonists**. They act on **$\mu$-opioid receptors** in the gastrointestinal tract to decrease longitudinal muscle contraction and increase segmented tone. This results in a significant **decrease in gastric motility** and delayed transit time, leading to constipation. **High-Yield Clinical Pearls for NEET-PG:** * **Methylnaltrexone & Alvimopan:** These are peripheral $\mu$-antagonists used specifically for opioid-induced constipation and postoperative ileus because they do not cross the blood-brain barrier. * **Loperamide:** A $\mu$-agonist used as an anti-diarrheal; it decreases motility but lacks central analgesic effects. * **Prokinetic Agents:** Drugs like Metoclopramide and Domperidone (D2 antagonists) are the primary classes used to *increase* gastric motility.

Q: What is the difference between ranitidine and cimetidine?

Ranitidine is 5 times more potent than cimetidine.. **Explanation:** This question tests your knowledge of **H2-receptor antagonists** [2], specifically comparing the first-generation drug (Cimetidine) with the second-generation drug (Ranitidine). **1. Why Option A is Correct:** Ranitidine is a more potent H2-receptor blocker than cimetidine [1], [2]. In clinical practice, ranitidine is approximately **5 to 10 times more potent** in inhibiting gastric acid secretion [1]. This increased potency allows for lower dosages and a longer duration of action compared to cimetidine. **2. Why the Other Options are Incorrect:** * **Option B:** This is factually reversed; ranitidine is the more potent agent. * **Option C:** Cimetidine, not ranitidine, has **anti-androgenic effects**. Cimetidine binds to androgen receptors and inhibits the metabolism of estradiol, which can lead to side effects like gynecomastia, galactorrhea, and reduced sperm count. Ranitidine lacks these effects. * **Option D:** Cimetidine is a notorious **Microsomal Enzyme Inhibitor** (inhibits Cytochrome P450). It significantly interferes with the metabolism of drugs like warfarin, phenytoin, and theophylline. Ranitidine has a much lower affinity for P450 enzymes and does not markedly inhibit hepatic metabolism at therapeutic doses. **High-Yield Clinical Pearls for NEET-PG:** * **Potency Hierarchy:** Famotidine > Ranitidine > Cimetidine [1]. (Famotidine is the most potent H2 blocker, ~20-50x more than cimetidine). * **Blood-Brain Barrier:** Cimetidine can cross the BBB and cause CNS side effects (confusion, hallucinations), especially in the elderly. * **Drug of Choice:** While H2 blockers are used for GERD and PUD, **Proton Pump Inhibitors (PPIs)** have largely replaced them as the first-line treatment due to superior efficacy [1]. * **Tachyphylaxis:** A unique feature of H2 blockers is the rapid development of tolerance (tachyphylaxis) within 3-7 days of use.

Question 1

What is the most important receptor involved in chemotherapy-induced vomiting?

Accepted Answer

Serotonin 5-HT3 receptor

Answer

Histamine H1 receptor

Answer

Dopamine D2 receptor

Answer

Opioid µ receptor

Question 2

Which of the following is NOT a pharmacologic therapeutic option for achalasia?

Accepted Answer

Beta blockers

Answer

Nitrates

Answer

Botulinum toxin

Answer

Sildenafil

Question 3

Extrapyramidal symptoms are seen with the use of which of the following medications?

Accepted Answer

Metoclopramide

Answer

Domperidone

Answer

Levosulpiride

Answer

Pramipexole

Question 4

Sulfasalazine exerts its primary action in ulcerative colitis by:

Accepted Answer

Inhibition of NF-kB activation

Answer

Folic acid synthesis

Answer

Formation of prostaglandins

Answer

Formation of interleukins

Question 5

What is the drug of choice for the prevention of NSAID-induced peptic ulcer disease?

Accepted Answer

Proton pump inhibitors

Answer

H2 receptor blockers

Answer

Macrolide antibiotic

Answer

Sucralfate

Question 6

Which of the following is not a prokinetic agent?

Accepted Answer

Diphenoxymethane

Answer

5-HT4 agonist

Answer

Dopamine D2 blocker

Answer

Macrolides

Question 7

Sulfasalazine is used in which of the following conditions?

Accepted Answer

Ulcerative colitis

Answer

Gout

Answer

Irritable bowel disease

Answer

Idiopathic osteoarthritis

Question 8

Which of the following agents decreases gastric motility?

Accepted Answer

Naloxone

Answer

Morphine

Answer

Codeine

Answer

Pethidine

Question 9

Proton pump inhibitors suppress gastric acid secretion by inhibition of which pump?

Accepted Answer

H+/ K+ ATPase pump

Answer

H+/Cl- ATPase pump

Answer

Na/Cl- ATPase pump

Answer

Na+/K+ ATPase pump

Question 10

What is the difference between ranitidine and cimetidine?

Accepted Answer

Ranitidine is 5 times more potent than cimetidine.

Answer

Cimetidine is 5 times more potent than ranitidine.

Answer

Ranitidine has androgenic action.

Answer

Ranitidine more markedly inhibits hepatic metabolism.

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?